ERBB2 and gastric cancer: Collectively, all these results suggested CD40 ×HER2 bsAb generated a compound and synergistic antitumor response with HER2 blockade and CD40 targeted costimulatory activity, which increases M1-like phenotype of TAMs and overcomes trastuzumab resistance in HER2-positive GC.